Vaccinex, Inc. (VCNX)
OTCMKTS · Delayed Price · Currency is USD
1.250
+0.470 (60.26%)
Aug 19, 2026, 3:08 PM EST
Vaccinex Revenue
In the year 2024, Vaccinex had annual revenue of $601.00K with 5.44% growth. Vaccinex had revenue of $213.00K in the quarter ending December 31, 2024.
Revenue
601.00K
Revenue Growth
+5.44%
P/S Ratio
4.45
Revenue / Employee
24.04K
Employees
27
Market Cap
2.68M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 601.00K | 31.00K | 5.44% |
| Dec 31, 2023 | 570.00K | 295.00K | 107.27% |
| Dec 31, 2022 | 275.00K | -625.00K | -69.44% |
| Dec 31, 2021 | 900.00K | 275.00K | 44.00% |
| Dec 31, 2020 | 625.00K | 102.00K | 19.50% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| CASI Pharmaceuticals | 20.11M |
| International Stem Cell | 9.51M |
| Pacific Software | 2.40M |
| Zenith Capital | 500.00K |
| Eastgate Biotech | 137.64K |
| Enzolytics | 46.59K |
| VitaSpring Biomedical | -1.49M |
Vaccinex News
- 6 weeks ago - Vaccinex to Report New Biomarker Data and Plans for Phase 2B Clinical Trial of Pepinemab in AD at the Alzheimer's Association International Conference in London on July 13, 2026 - GlobeNewsWire
- 4 months ago - Vaccinex Reports 2025 Annual Financial Results - GlobeNewsWire
- 8 months ago - Vaccinex announces $60M revenue sharing agreement with PDV - TheFly
- 1 year ago - Vaccinex to reports new clinical results on pepinemab at ASCO meeting - TheFly
- 1 year ago - Vaccinex to Report Promising New Clinical Results of Neoadjuvant Treatment with Pepinemab to Enhance Immunotherapy in Patients with Head and Neck Cancer at ASCO Annual Meeting - GlobeNewsWire
- 1 year ago - Vaccinex to report new clinical data on pepinemab in enhancing immunotherapy - TheFly
- 1 year ago - Vaccinex to Report Promising New Clinical Data Revealing Pepinemab's Unique Mechanism to Enhance Immunotherapy at Annual Meeting of American Association for Cancer Research (AACR) - GlobeNewsWire
- 1 year ago - Vaccinex to delist common stock from Nasdaq - TheFly